98%
921
2 minutes
20
The COVID-19 pandemic has created significant concern for everyone. Recent data from many worldwide reports suggest that most infections are caused by the Omicron variant and its sub-lineages, dominating all the previously emerged variants. The numerous mutations in Omicron's viral genome and its sub-lineages attribute it a larger amount of viral fitness, owing to the alteration of the transmission and pathophysiology of the virus. With a rapid change to the viral structure, Omicron and its sub-variants, namely BA.1, BA.2, BA.3, BA.4, and BA.5, dominate the community with an ability to escape the neutralization efficiency induced by prior vaccination or infections. Similarly, several recombinant sub-variants of Omicron, namely XBB, XBD, and XBF, etc., have emerged, which a better understanding. This review mainly entails the changes to Omicron and its sub-lineages due to it having a higher number of mutations. The binding affinity, cellular entry, disease severity, infection rates, and most importantly, the immune evading potential of them are discussed in this review. A comparative analysis of the Delta variant and the other dominating variants that evolved before Omicron gives the readers an in-depth understanding of the landscape of Omicron's transmission and infection. Furthermore, this review discusses the range of neutralization abilities possessed by several approved antiviral therapeutic molecules and neutralizing antibodies which are functional against Omicron and its sub-variants. The rapid evolution of the sub-variants is causing infections, but the broader aspect of their transmission and neutralization has not been explored. Thus, the scientific community should adopt an elucidative approach to obtain a clear idea about the recently emerged sub-variants, including the recombinant variants, so that effective neutralization with vaccines and drugs can be achieved. This, in turn, will lead to a drop in the number of cases and, finally, an end to the pandemic.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9866114 | PMC |
http://dx.doi.org/10.3390/v15010167 | DOI Listing |
Curr Pharm Des
September 2025
Bogomoletz Institute of Physiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine.
Introduction: Pharmacological studies in vitro demonstrate the preventive and therapeutic potential of green tea and its constituent epigallocatechin-3-gallate (EGCG) in the fight against coronavirus disease 2019 (COVID-19). Previously reported correlations between per capita green tea consumption and COVID-19 morbidity/mortality suggest similar effects in vivo. Considering that some recent SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) sub-variants are less influenced by EGCG, this study aimed to determine whether this affects the aforementioned correlations, focusing on comparisons between the periods before (2021) and after (2022-2024) the emergence of the Omicron variant.
View Article and Find Full Text PDFVirus Res
August 2025
Center for Molecular Diagnosis and Precision Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, 1519 Dongyue Dadao, Nanchang 330209, China; Jiangxi Provincial Center for Advanced Diagnostic Technology and Precision Medicine, The First Affiliated Hospital, Jiangxi
The ongoing mutation and evolution of SARS-CoV-2 have posed a severe threat to global health, and their functional impact remains to be further characterized. Here, we analyzed the selection pressure from 49 Omicron sub-strains at the gene and amino acid levels. We also examined the impact of mutations on the binding affinity between the receptor binding domain (RBD) and angiotensin-Converting Enzyme 2 (ACE2) and evaluated the immune escape ability of RBD responding to the monoclonal antibodies (mAbs) through molecular dynamics simulation on eight representative Omicron sub-variants (B.
View Article and Find Full Text PDFVaccines (Basel)
August 2025
Munich Biomarker Research Center, Institute of Laboratory Medicine, TUM University Hospital German Heart Center, Lazarettstr. 36, 80636 Munich, Germany.
: Systematic studies providing differentiated insight into the contribution of immunity directed against conserved and non-conserved epitopes of SARS-CoV-2 Spike on long-term protection are rare and insufficiently guide future pan-variant vaccine research. The present observational cohort study aimed to evaluate the correlation of neutralizing antibody levels and cellular immunity against the Spike protein with symptomatic Omicron breakthrough infection. : Neutralizing antibody levels against multiple (sub)variants were analyzed 6 months following the second wild-type mRNA vaccination and 6 months after booster in 107 subjects using a multiplex surrogate virus neutralization assay.
View Article and Find Full Text PDFVaccine
August 2025
Department of Immunization, Vaccines, and Biologicals, World Health Organization, Geneva, Switzerland. Electronic address:
As the COVID-19 pandemic has evolved, interpreting COVID-19 vaccine effectiveness (VE) has become increasingly complex due to time-varying factors that need to be disentangled, such as waning of protection and new SARS-CoV-2 variant or sub-variant emergence. Given that policymakers and regulatory authorities use COVID-19 VE data to inform COVID-19 vaccine and immunization program recommendations, the World Health Organization convened a virtual meeting on May 7, 2024. At the meeting, approaches for addressing time-varying factors were discussed using examples of COVID-19 VE studies applying a test-negative design.
View Article and Find Full Text PDFPhys Chem Chem Phys
September 2025
Physical and Biomolecular Research Lab, Department of Chemical Sciences, Indian Institution of Science Education and Research, Berhampur, Odisha, 760010, India.
The emergence of new SARS-CoV-2 Omicron sub-variants with faster transmission has necessitated accelerated scientific efforts to confront a possible health emergency. Conventional anti-CoV strategies targeting viral proteins often fail due to frequent mutations. Thus, targeting the conserved host receptor angiotensin-converting enzyme 2 (hACE2), which mediates viral entry interaction with the spike protein's receptor-binding domain (RBD), presents a rational therapeutic alternative.
View Article and Find Full Text PDF